2026-09-10Screening report
Data as of 2026-09-10US market
Summary
September 10, 2026 screening identifies extreme valuation dislocations in Cooper Companies, DexCom, Amgen, Pinterest, and Expedia.
Screening weights
Fundamental improvement25%
Candidate comparison
| Rank | Ticker | Sector | 3M return | Revenue YoY | OPM Δ | FCF | Score |
|---|
| 1 | Cooper Companies | Healthcare | -18.5% | +7.5% | +1.1%p | Positive | 9.0 |
| 2 | DexCom | Healthcare | -22.4% | +15.3% | +1.8%p | Positive | 8.9 |
| 3 | Amgen | Healthcare | -7.4% | +10.0% | +1.2%p | Positive | 8.7 |
| 4 | Pinterest | Communication | -15.2% | +21.0% | +3.4%p | Positive | 8.5 |
| 5 | Expedia | Consumer | -8.9% | +6.2% | +1.5%p | Positive | 8.4 |
| 6 | Salesforce | Technology | -7.9% | +8.4% | +2.4%p | Positive | 8.3 |
| 7 | Lululemon | Consumer | -15.1% | +9.8% | +0.8%p | Positive | 8.1 |
| 8 | Gartner | Technology | -10.1% | +6.8% | +1.1%p | Positive | 7.9 |
| 9 | Snowflake | Technology | -13.5% | +29.1% | +3.2%p | Positive | 7.8 |
| 10 | PayPal | Financials | -5.8% | +7.2% | +1.4%p | Positive | 7.7 |
Screened names (observations)
Observation
Plunged -14.1% today on temporary Americas distributor destocking despite beating Q3 adjusted EPS; 66% gross margin and contact lens end-demand remain solid.
Catalysts to watch
- Americas optical distributor inventory normalization
- MyDay daily toric and multifocal lens adoption
Risks
- Extended optical channel destocking into Q4
Framework exit signals
- CooperVision constant-currency organic growth falls below +3%
Metrics to watch
- CooperVision constant-currency revenue
- Gross profit margin
Observation
RSI under 26 on persistent rebate noise; core revenue expanded +15.3% YoY with +1.8%p operating margin expansion and OTC Stelo rollout.
Catalysts to watch
- Stelo OTC biosensor retail volume expansion
- Commercial payer coverage for non-insulin Type 2 diabetics
Risks
- Rebate structure pressure in US pharmacy channels
Framework exit signals
- G7 sensor volume growth drops below +10% YoY
Metrics to watch
- G7 sensor volume growth
- Stelo OTC adoption rate
Observation
Deep value following recent -10.1% sell-off on competitor trial noise; trading at multi-year discount supported by $10.5B FCF and 3.1% dividend yield.
Catalysts to watch
- MariTide Phase 2 obesity data readouts
- Double-digit volume growth in Repatha and Tezspire
Risks
- GLP-1 obesity trial disclosures by competitors
Framework exit signals
- MariTide development safety discontinuation
Metrics to watch
- MariTide Phase 2 trial updates
- Core product volume growth
Observation
Oversold -7.6% drop on CFO departure; fundamentals accelerating with +21% YoY revenue growth, +3.4%p OPM expansion, and $2.7B net cash.
Catalysts to watch
- Performance+ AI ad campaign adoption
- Amazon and Google third-party ad monetization
Risks
- CFO leadership transition friction
Framework exit signals
- Global MAUs turning negative QoQ
Metrics to watch
- Global MAU growth
- International ARPU
Observation
Crude oil hitting $102 triggered indiscriminate travel sell-off; trading at ~11x forward P/E with +20% B2B growth and $2.1B annual FCF.
Catalysts to watch
- B2B enterprise travel platform partnerships
- One Key loyalty program repeat booking gains
Risks
- Sustained jet fuel price surge dampening travel
Framework exit signals
- Gross bookings growth below +2.0% YoY
Metrics to watch
- B2B gross bookings
- Lodging room nights growth
AlphaSignal: Top 5 Oversold US Stocks Poised for Rebound (Sep 10, 2026)
1. Executive Summary
- Date: September 10, 2026 | Market: US Equities (S&P 500 / Russell 1000)
- Overview: August PPI jumping to 5.4% and WTI crude surpassing $102 sparked broad selling, creating acute oversold dislocations in quality compounders.
- Criteria: Daily drop / RSI < 30, expanding revenue & OPM, positive FCF.
2. Candidate Comparison Table
- COO (9.0) - Healthcare | 3M: -18.5% | Rev: +7.5% | OPM: +1.1%p | FCF: Positive
- DXCM (8.9) - Healthcare | 3M: -22.4% | Rev: +15.3% | OPM: +1.8%p | FCF: Positive
- AMGN (8.7) - Healthcare | 3M: -7.4% | Rev: +10.0% | OPM: +1.2%p | FCF: $10.5B
- PINS (8.5) - Comm | 3M: -15.2% | Rev: +21.0% | OPM: +3.4%p | FCF: $650M
- EXPE (8.4) - Consumer | 3M: -8.9% | Rev: +6.2% | OPM: +1.5%p | FCF: $2.1B
- CRM (8.3) | 7. LULU (8.1) | 8. IT (7.9) | 9. SNOW (7.8) | 10. PYPL (7.7)
3. Final Top 5 Recommendations
- COO (Cooper Companies): -14.1% plunge on distributor destocking noise; 66% gross margin intact, contact lens demand strong.
- DXCM (DexCom): RSI < 28 on transitory rebate noise; +15.3% rev, expanding OPM; Stelo OTC rollout.
- AMGN (Amgen): -10.1% sell-off on competitor noise; $10.5B FCF, 3.1% dividend yield margin of safety.
- PINS (Pinterest): -7.6% drop on CFO departure; +21% rev growth, $2.7B net cash fortress.
- EXPE (Expedia): ~11x forward P/E on oil spike fear; +20% B2B growth, $2.1B annual FCF.
4. Conclusion
- Highest Conviction: COO | Deepest Oversold: DXCM | Defensive Value: AMGN | Growth: PINS | Cash Flow: EXPE
- Watchlist: CRM, LULU, IT, SNOW, PYPL
Not investment advice. Scores and lists are relative snapshots.
← All notes